RESEARCH



Continuous nerve block versus thoracic epidural analgesia for post-operative pain of pectus excavatum repair: a systematic review and meta-analysis



Li-Jung Chen¹, Shih-Hong Chen¹, Yung-Lin Hsieh¹ and Po-Chuan Yu^{1*}

Abstract

Surgery to repair pectus excavatum (PE) is often associated with severe postoperative pain, which can impact the length of hospital stay (LOS). While thoracic epidural analgesia (TEA) has traditionally been used for pain management in PE, its placement can sometimes result in severe neurological complications. Recently, paravertebral block (PVB) and erector spinae plane block (ESPB) have been recommended for many other chest and abdominal surgeries. However, due to the more severe and prolonged pain associated with PE repair, it is still unclear whether continuous administration of these blocks is as effective as TEA. Therefore, we conducted this systematic review and meta-analysis to demonstrate the equivalence of continuous PVB and ESPB to TEA.

Keywords Pectus excavatum, Thoracic epidural analgesia, Paravertebral block, Erector spinae plane block

Background

Pectus excavatum (PE) is a chest wall deformity [1] that not only affects appearance but may also limit cardiac and pulmonary functions [2, 3]. There are two primary procedures to repair this condition: the Ravitch procedure, which involves a sternal wedge osteotomy, and the Nuss procedure, a minimally invasive approach that involves inserting a metal bar under the sternum, are performed. However, both of these procedures can result in severe pain [4, 5]. Thoracic epidural analgesia (TEA) has a better analgesia effect than intravenous patient-controlled analgesia (PCA) and has been advocated for post-operative PE pain [6]. This procedure involves the placement

*Correspondence:

yu136917@gmail.com

of either a needle (single injection) or a catheter (continuous infusion) into the epidural space via landmarkguiding, sonography, or fluoroscopy. Subsequently, the solution blocks the ventral and dorsal nerve roots passing through the epidural space [7]. In general terms, TEA catheter implants are considered safe; however, this procedure can lead to severe complications, including spinal cord injury, epidural hematoma, subarachnoid block and epidural abscess [8–10]. Multiple studies [9, 11] have reported chronic and severe neurological complications associated with the use of TEA during the Nuss procedure. Consequently, these adverse outcomes have raised concerns about the safety of TEA.

Other alternatives to TEA, such as paravertebral block (PVB) [11] and erector spinae plane block (ESPB) [12, 13] are also used for post-operative pain management. PVB is a type of peripheral nerve block in which a local anesthetic, with or without other medication, is injected into the paravertebral space. This technique aims to



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Po-Chuan Yu

¹Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No.289, Jianguo Rd., Xindian Dist, 231405 New Taipei City, Taiwan

anesthetize the spinal nerves at the paravertebral space, which is immediately lateral to the intervertebral foramina [14]. This produced an ipsilateral segmental somatic block and provides analgesia for chest and abdomen surgeries. The single PVB injection of 15-20 ml or 0.25ml/ kg cause unilateral somatic block over 5 dermatomes and sympathetic block over 8 dermatomes [15]. The PVB catheters are usually placed at T4-T6 bilaterally for PE repair. The PVB doses for PE repair are initial 10–20 ml or 0.3-0.6 ml/kg and continous infusion at rate of 5-10ml/hr or 0.125-0.25 ml/kg/hr per catheter [16-18]. The common advantages of PVB compared to TEA are simple, easy to learn, less sympathetic blockade leading to less hypotension and lower risk of urine retension [19]. The similar risks are deep bleeding if coagulopathy, inadvertent vascular, pleural or dural puncture, horner's syndrome and local anesthetic systemic toxicity [15].

ESPB is another type of peripheral nerve block that involves a local anesthetic, with or without other medication, into erector spinae plane space. The anesthetic diffuses into the paravertebral space anteriorly, working similarly to PVB. An interfascial spread that blocks the posterior rami of spinal nerves may also be another mechanism [20]. The single ESPB injection at T4-6 of 20-30 ml cause sensory block ranging from T1 to L3 [21]. Radiological investigations report that the 2.5 ml local anesthetic solution cover one thoracic dermatome [22]. The ESPB catheters are also placed bilaterally at T4-T6 for PE repair [23–25]. The suggestive ESPB dose for PE repair is 10-20 ml or 0.4ml/kg for loading and continous infusion at rate of 6-12ml/hr. The benefits of ESPB are no sympathectomy if absence of epidural or paravertebral spread, lower risk of urine retension, lower bleeding risk in patients with coagulopathy, no risk for respiratory compression and outpatient ambulatory pump [23–25]. The similar risks are inadvertent vascular or pleural puncture and local anesthetic systemic toxicity. Sensory block was might be in ventral and dorsal dermatomes with variation among studies but mainly posterior to the midaxillary line and minimally to anterior side [26, 27]. Both PVB and ESPB are typically performed under sonography and can be administered as a single injection or continuous infusion. Due to their longer distance from the spinal cord, PVB and ESPB are less likely to cause neurological injury [16, 17, 23] and have been used in numerous thoracic and abdominal surgeries [15, 28, 29]. Several studies have reported their effectiveness and safety; however, there has been no systematic review or meta-analysis regarding the use of nerve blocks in PE repairs. Therefore, this study aims to support the hypothesis that continuous nerve block is equivalent to TEA in managing pain after PE repair.

Methods

Study design

This meta-analysis aimed to assess the effects of continuous PVB and ESPB versus TEA on LOS as primary outcome in patients with PE repair. Our study was conducted in accordance with PRISMA guidelines, a commonly used tool to correctly elaborating reviews that evaluate the effects of interventions [30] (Fig. 1).

Inclusion criteria

The inclusion criteria for studies were as follows: the patients underwent the repair of PE using sterna wedge osteotomy or minimally invasive approach, regardless of the sex, race, age, height, and weight and studies that compared LOS, pain score, and opioid usage between TEA and continuous infusion of ESPB or PVB; both retrospective and prospective studies were eligible.

Search and selection


PubMed, EMBASE, and Cochrane Library databases were searched for the eligible studies published from their inception until January 2023. We did not exclude studies by date, region, or language. MeSH terms including "Nerve Block/pharmacology"[Mesh], "Nerve Block/standards"[Mesh], "Nerve Block/therapeutic use"[Mesh], "Nerve Block/therapy"[Mesh], "Analgesia, Epidural"[Mesh], "Analgesia, Epidural"[Mesh], "Analgesia, Epidural/adverse effects"[Mesh], "Analgesia, Epidural/statistics and numerical data"[Mesh], "Analgesia, Epidural/therapeutic use"[Mesh], "Analgesia, Epidural/ therapy"[Mesh]), "Funnel Chest/surgery"[Mesh], "Funnel Chest/therapy"[Mesh], "Funnel Chest"[Mesh], "Pain Measurement"[Mesh], "Visual Analog Scale"[Mesh], "Analgesics, Opioid" [Mesh], "Analgesics, Opioid/administration and dosage"[Mesh], "Analgesics, Opioid/therapeutic use" [Mesh] and "Length of stay" [Mesh] were used in combination with plain text to search PubMed. Similar strategies were applied to search the other databases. The search strategies are provided in detail in Supplement 1.

Two independent reviewers selected the eligible studies. Any disagreements were resolved by the reviewers; a third reviewer was consulted if the reviewers cannot reach an agreement.

Data collection

Data extracted from each study included: (i) general study characteristics: study design, country, and enrolment period; (ii) study population characteristics: age, preoperative PE severity index (e.g., Haller index [HI]); (iii) characteristics of the intervention: the level of epidural catheters or continued nerve block catheters that were placed and the medication used for TEA or continued nerve block; (iv) primary outcome measure was LOS; (v) Secondary outcome measures were post-operative







pain scores, total opioid usage, and post-operative nausea and vomiting (PONV).

One reviewer extracted data sets from each eligible study, which were further validated by a second reviewer. Continuous variables reported as mean and standard deviation (SD) were extracted without any changes. If needed, the values were driven from the graphs. However, variables reported as median and interquartile range were converted before extraction. Methods of conversion have been reported before [31].

Risk of bias

The methodological quality of the randomized controlled trial (RCT) was evaluated using the updated Cochrane risk-of-bias tool for randomized trials (RoB 2) [32]. The risk of bias was assessed using the RoB 2 tool, which evaluates the risk-of-bias across five domains and provides a judgment on a 5-point scale. Non-randomized studies were assessed using the Cochrane risk-of-bias tool for non-randomized studies of interventions (ROBINS-I), which assigns studies a rating of low, moderate or high risk (3-point scale) based on seven domains [33].

Statistics

Meta-analyses were performed by Review Manager Software (version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) using a random-effects model. This model was chosen because the treatment effect can vary across each study due to differences in treatment protocols. The primary and secondary outcomes were estimated by the mean difference (MD) and its 95% confidence interval (CI). Statistical heterogeneity was assessed by the Cochran Q statistic and quantified by the I^2 statistic. Outcomes are presented in forest plots. A subgroup analysis was not predetermined. A P-value ≤ 0.05 was considered statistically significant.

Results

Study selection

A total of 43 studies were identified from the three databases, PubMed (n=14), EMBASE (n=24), and Cochrane (n=5). Of them, 15 duplicates were removed. The title and abstract of the remaining 28 studies were screened for eligibility. Twenty studies were excluded due to being irrelevant, case reports, or conference abstracts, among other reasons listed in Fig. 1. The full text of the eight remaining articles was read and thoroughly assessed for eligibility. However, one article was excluded because the patients in both groups had single injections, not continued infusion. The remaining seven studies [16–18, 23–25, 34] were considered eligible for pooling by quantitative synthesis.

Study characteristics

Methods

Among the studies, six were retrospective cohorts [16, 17, 23–25, 34] and one was a prospective observational multi-institutional study [18]. No RCT was found. A total of 644 patients were included. A study did not mention the mean age of participants [34], but it ranged from 14.5 to 15.8 years. The mean of HI was not reported in studies by Loftus et al. [34] and Hall et al.[16], but it ranged from 4.2 to 7.3. Most participants underwent minimally invasive repair of the PE by the Nuss procedure, except 15 participants who underwent the Ravitch procedure in the study by Loftus et al. [34]. Continuous PVB was provided in four studies [16–18, 34]. The patients in three studies received analgesia via ESPB catheter [23–25].

Interventions

Two studies [16, 24] reported the needle used in the nerve block group: 18G Pajunk needle and 20G B. Braun catheter. The location of TEA catheter placement was not mentioned in one study [34] and mainly reported at T4-T7 in other studies. All the studies except the one by Loftus et al. [34] did not report the formulation, bupivacaine or ropivacaine with clonidine or dexmedetomidine,

of continuous peripheral nerve block infusion. Additional PCA pumps were administered in one study [17]. Three studies [16, 17, 24] reported the location of TEA catheter placement, which was mostly between T4-5, T5-6, or T6-7. In studies with mention, the epidural space was infused with bupivacaine or ropivacaine in combination with an opioid. Main characteristics of these studies were listed in Table 1.

Outcomes

Five studies reported the LOS [18, 23–25, 34]. Pain score (mostly measured using NRS in those studies describing it), opioid usage, and events of PONV were at least reported by one study each. A summary of main outcomes is provided in Table 2.

Risk of bias

Two studies [16, 34] were assessed as having a serious risk of bias, while five studies were judged as having a moderate risk [17, 18, 23–25] (see Fig. 2).

Length of hospital stay

Five studies reported LOS [18, 23–25, 34]. The pooled effect estimate showed a significantly reduced LOS in the nerve block group than in the TEA group (Fig. 3; MD, -1.24; 95% CI, -1.45 to -1.03; P<0.001). No significant between-subgroup differences ($I^2 = 0\%$; P=0.92) were observed. (PVB; MD -1.22, 95% CI, -1.92 to -0.51; P<0.001; ESPB; MD -1.25, 95% CI, -1.5 to -1.04; P<0.001)

Pain score

All the studies reported pain scores. The synthesis showed a significantly lower pain score in the TEA group by 0.83 (95% CI, 0.55 to 1.11; P<0.001), 0.75 (95% CI, 0.35 to 1.15; P<0.001), and 0.63 (95% CI, 0.35 to 0.91; P<0.001) on post-operative days (POD) 1, 2, and 3, respectively (see Fig. 4). No significant betweensubgroup differences ($I^2 = 0\%$; P=0.43) were observed on POD1 (PVB; MD 0.69, 95% CI, 0.13 to 1.24; P=0.02; ESPB; MD 0.99, 95% CI, 0.48 to 1.5; P<0.001). There was an insignificant between-subgroup difference ($I^2 = 57.1\%$; P=0.13) on POD2 and the difference between PVB and TEA was insignificant while TEA group has a lower pain score than ESPB group (PVB; MD 0.24, 95% CI, -0.55 to 1.03; P=0.55; ESPB; MD 0.97, 95% CI, 0.48 to 1.45; P < 0.001). There was no significant between-subgroup difference ($I^2 = 0\%$; P=0.41) on POD3 and the difference between PVB and TEA was also insignificant while TEA group still has a lower pain score than ESPB group (PVB; MD 0.40, 95% CI, -0.23 to 1.03; P=0.21; ESPB; MD 0.63, 95% CI, 0.35 to 0.91; P<0.001).

Table 1 Study characteristics

Study	Nation	Study design	Treat- ment arm	Period	Num- ber of patients	Age (years)	Level of catheter	Medications	HI
Hall 2014 [16]	USA	Retrospective case-control study	PVB	2009/06- 2011/08	10	15.5±2.3	T6 TP	7ml/hr 0.2% R	NR
			TEA	2010/10- 2012/01	10	14.5±2.5	T5	7ml/hr 0.2% R	NR
Loftus 2016 [<mark>34</mark>]	USA	Retrospective observa- tion study	PVB	2009/01- 2012/12	28	NR	NR	NR	NR
			TEA		80	NR	NR	NR	NR
Beltran 2017 [17]	Canada	Retrospective observa- tion study	PVB	2011– 2013	7	15.7±1.3	T45,T56	0.25–0.5 mg/kg 0.2% R with PCA	4.8±1.6
			TEA		8	15.8±1.6	T567	0.1% R or 0.125% B with fentanyl 2mcg/ml	4.5±1.4
Muhly 2019 [18]	USA	Prospective observation multi-institutional study	PVB	2014/6– 2015/8	56	14.9±2.8	D	D	4.8±1.6
			TEA		114	14.9 ± 2.4	D	D	4.5 ± 1.4
Bliss 2022 [25]	USA	Retrospective observa- tion study	ESP	NR	30	15.4±1.2	T5-6	0.5% R 6ml/hrinitial (0.25 mg/kg/hr max)	7.3±1.6
			TEA		30	14.9±1.3	NR	0.2% R with hydromor- phine 2–5mcg/ml	4.2±1.4
Santana 2022 [23]	USA	Retrospective observa- tion study	ESP	2014/1– 2020/1	19	15.6±1.8	T4-T6	0.2% R with 1mcg/ml clonidine	5.2±1.1
			TEA		41	15 ± 2.2	NA	NR	5.5 ± 2.2
Walter 2023 [24]	USA	Retrospective observa- tion study	ESP	2019/1– 2021/5	97	15.3±2.3	T5 TP	0.125–0.2% R 6–8ml/hr with clonidine 0.5mcg/ ml	4.8±4.6
			TEA		114	15 ± 3	T45T56	0.2% R 10–12ml/hr	4.9 ± 4.6

TP: transverse process; R: ropivacaine; NR: not reported; B: bupivacaine; D: differs in each hospital

Opioid usage

Five studies reported opioid usage on post-operative day 1 to day 3 [16–18, 24, 25]. The meta-analysis showed no significant difference on post-operative day 1 (MD 0.29, 95% CI, -0.05 to 0.63; P=0.10) and 2 (MD 0.19, 95% CI, -0.02 to 0.39; P=0.08) but significantly high opioid usage in TEA group on post-operative day 3 (Fig. 5; MD -0.02, 95% CI, -0.03 to -0.01; P<0.001). No significant betweensubgroup differences were observed on POD1 ($I^2 = 0\%$; P=0.89, PVB; MD 0.23, 95% CI, -0.11 to 0.56; P=0.18; ESPB; MD 0.3, 95% CI, -0.65 to 1.25; P=0.54), on POD2 $(I^2 = 0\%; P = 0.94, PVB; MD 0.18, 95\% CI, -0.15 to 0.51;$ P=0.28; ESPB; MD 0.2, 95% CI, -0.2 to 0.61; P=0.32) and on POD3 (I² = 60.7%; P=0.11, PVB; MD 0.02, 95% CI, -0.03 to 0.06; P=0.46; ESPB; MD -0.02, 95% CI, -0.03 to -0.01; P=0.37). However, due to high-level of heterogeneity in test for subgroup differences on POD3, the heterogeneity decreased to low-level ($I^2 = 31.2\%$; P=0.23) after we removed the study by Walter [24] and POD3 opioid usage difference became insignificant (MD 0.01, 95% CI, -0.03 to 0.06; P=0.61).

Event of post-operative nausea or vomiting

Three studies reported events of PONV [17, 18, 24]. The analysis showed a significant difference in more events of PONV in TEA group than nerve block group (Fig. 6; Risk

ratio 0.37, 95% CI, 0.14 to 0.99; P=0.05). However, there was a high-level of heterogeneity ($I^2 = 70\%$; P=0.03).

Discussion

This systematic review and meta-analysis compared continuous ESPB and PVB with TEA about LOS as the primary outcome. However, no RCT was found in this regard. Seven non-randomized studies were included, with a total of 644 patients. The synthesis of the result reported that continuous nerve blockage reduced LOS by 1.24 days compared to TEA with statistical significance in patient with PE repair (Fig. 3). Several reasons may cause this result. Firstly, the duration of urinary catheter usage was much longer in the TEA group [18, 25]. Recent studies reported around 10% patients who underwent TEA experienced urinary retention [35, 36] due to the effect of epidural mixture on their urethral sphincter function [37]. This can cause difficulties voiding, leading to the need for longer use of indwelling urinary catheters [37]. However, the use of catheters can limit a patient's ability to move around freely [38]. In other meta-analysis involving patients who underwent thoracotomy, they also reported that urinary retention is more common in TEA group than PVB group [39]. Secondly, patients in the TEA group reported experiencing numbness and weakness in their upper arms, chest, and sometimes even their

Study	Treatment arm	LOS (days)	Time to remove analgesia catheter (days)	Pain Score on POD 1 POD 2 POD 3	Opioid usage (mg/kg) on POD 1 POD 2 POD 3	
Hall 2014 [16]	PVB	NR	3	3.367±1.548 1.667±2.752 2.667±2.408	0.14±0.12 0.14±0.1 0.14±0.1	NR
	TEA	NR	3	3.133±1.118 2.833±2.58 3.167±2.408	0.157±0.181 0.163±0.138 0.163±0.172	NR
oftus 2016 [34].	PVB	3.3±2.339	NR	3.523±4.7 3.113±4.421 2.893±4	NR	NR
	TEA	5.3±3.775	NR	3.3±5.662 3.267±5.36 2.93±4.462	NR	NR
Beltran 2017 [17]	PVB	NR	NR	2.5±1.4 2±1.1 1.6±1.2	3.4±1.6 3.4±2 3.2±1.5	2
	TEA	NR	NR	2.2 ± 1.6 2.7 ± 2.4 2.5 ± 2.4	1.4 ± 1.4 2 ± 2 3.1 ± 2.3	4
Muhly 2019 [18]	PVB	3±1.52	D	3.333±2.282 3±1.522 3±1.522	0.31±0.175 0.33±0.19 0.08±0.167	13
	TEA	4±1.5	D	2.33 ± 2.252 2.33 ± 2.252 2.33 ± 2.252	0.0066±0.015 0.0166±0.037 0.06±0.112	45
Bliss 2022 [<mark>25</mark>]	ESP	2.9±0.87	5±1.34	3.9±1.82 3.97±1.82 4.32±2.53	1±0.575 0.6785±0.3875 0.7125±0.4964	NR
	TEA	3.78±0.82	2.84±0.3	2.72±1.37 2.83±1.32 3.38±1.67	0.2125±0.0875 0.2625±0.1267 0.8339±0.366	NR
Santana 2022 [23]	ESP	3.3±0.5	NR	4.1±1.682 4.067±1.282 4.067±1.442	NR	NR
	TEA	4.7±0.9	NR	2.667±0.922 3±0.307 3.333±0.922	NR	NR
Walter 2023 [24]	ESP	2±0	POD 5	4.48±1.36	0.1 ±0.0978 0.0167±0.0376 0±0	4
	TEA	3.33±0.75	POD 2	3.83±1.59	0.28±0.06 0.013±0.03 0.02±0.045	33

Table 2 Study outcomes

lower legs [10, 24]. This can result in a decline in ambulation due to reduced muscle power in the limbs, or due to the patient's unwillingness to move. Thirdly, the use of opioids and PONV also play an important role in determining discharge, which we will discuss further later on. Lastly, TEA provided excellent analgesia, which resulted in patients having a painless experience and making it difficult to discontinue the treatment [25]. This can sometimes lead to rebound pain after the weaning process [23]. Pain scores were significantly lower in TEA group from POD 1 to POD 3 compared to nerve block group [25, 40] (Fig. 4). This is likely due to the excellent efficacy of TEA. In another meta-analysis involving patients who underwent thoracotomy, another painful thoracic surgery traditionally treated with TEA, the TEA group had lower pain scores than the continuous nerve block group in the first 48 h [39]. However, in subgroup analysis, pain score was significantly lower in TEA group than PVB only on POD 1 while pain scores on POD 2 and 3 were not significantly different. This result was also noted in study of

	D1	D2	D3	D4	D5	D6	D7	Overall
Hall et al. 2014	×	X	-	-	+	-	-	×
Loftus et al. 2016	×	×	-	-	-	-	×	×
Beltran et al. 2017	+	-	-	-	+	-	+	-
Muchy et al. 2019	-	+	+	+	+	-	-	-
Bliss et al. 2022	-	×	-	-	+	+	+	-
Santana et al. 2022	+	+	-	-	-	+	-	-
Walter et al. 2023	-	+	+	+	-	×	-	-

Domains:

D1: Bias due to confounding

- D2: Bias in selection of participants into the study
- D3: Bias in classification of interventions
- D4: Bias due to deviations from intended interventions
- D5: Bias due to missing data
- D6: Bias in measurement of outcomes
- D7: Bias in selection of the reported result



Fig. 2 Risk of bias within studies

	NB				TEA			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 PVB									
Loftus 2016	3.4867	2.3254	28	5.3	3.775	80	2.9%	-1.81 [-3.01, -0.62] -	
Muhly 2019	3	1.52	56	4	1.5	114	14.0%	-1.00 [-1.48, -0.52]	
Subtotal (95% CI)			84			194	16.9%	-1.22 [-1.92, -0.51]	
Heterogeneity: Tau ² =	0.11; Chi ²	= 1.53, df	= 1 (P =	= 0.22); l ² = 3	35%				
Test for overall effect:	Z = 3.39 (I	P = 0.0007)						
1.1.2 ESPB									
Bliss 2022	2.9	0.87	30	3.78	0.82	30	16.8%	-0.88 [-1.31, -0.45]	_ _
Santana 2022	3.3	0.5	19	4.7	0.9	41	21.4%	-1.40 [-1.76, -1.04]	
Walter 2023	2	0.000001	97	3.3333333	0.7508554	114	44.9%	-1.33 [-1.47, -1.20]	
Subtotal (95% CI)			146			185	83.1%	-1.25 [-1.50, -1.01]	•
Heterogeneity: Tau ² =	0.03; Chi ²	= 4.23, df	= 2 (P =	= 0.12); I ² = 4	53%				
Test for overall effect:	Z = 9.99 (I	P < 0.0000	1)						
Total (95% CI)			230			379	100.0%	-1.24 [-1.45, -1.03]	◆
Heterogeneity: Tau ² =	0.02; Chi ²	= 6.39, df	= 4 (P =	= 0.17); l² = 3	37%				
Test for overall effect:	Z = 11.59	(P < 0.000	01)	,.					-2 -1 0 1 2 Favours NB Favours TEA
Test for subgroup diffe	erences: C	hi² = 0.01,	df = 1 (P = 0.92), I ²	= 0%				Favouis ND Favouis IEA


Fig. 3 Meta-analyses of the LOS

Liang et al. [19], which demonstrated the PVB group had higher pain scores in first 1–2 h and 4–6 h but there were no difference on 24 and 48 h postoperatively. While there were statistically significant differences in pain scores in our study and in patients with thoracotomy, these differences were small and not more than 1 point [39]. These small differences can be easily managed by additional oral or parenteral analgesia.

Opioid usage was not significantly different in the first two days after the operation. However, on POD 3, there was a significant difference in opioid usage (Fig. 5). This phenomenon might come from the removal of TEA catheter on POD2 or using clonidine as an adjuvant for ESPB

Α		NB			TEA			Mean Difference	м	ean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV,	Random, 95% CI	
2.1.1 PVB											
Beltran 2017	2.5	1.4	7	2.2	1.6	8	3.4%	0.30 [-1.22, 1.82]		_	
Hall 2014	3.367	1.548	10	3.133	1.118	10	5.6%	0.23 [-0.95, 1.42]		_ <u>_</u>	
Loftus 2016	3.4691	4.7864	28	3.3	5.662	80	1.7%	0.17 [-1.99, 2.33]			
Muhly 2019	3.333	2.282	56	2.33	2.252	114	14.8%	1.00 [0.28, 1.73]			
Subtotal (95% CI)			101			212	25.5%	0.69 [0.13, 1.24]		-	
Heterogeneity: Tau ² =	0.00; Chi	² = 1.76,	df = 3	(P = 0.6	2); I ² = (0%					
Test for overall effect:	Z = 2.43	(P = 0.02	2)								
2.1.2 ESPB											
Bliss 2022	3.9	1.82	30	2.72	1.37	30	11.8%	1.18 [0.36, 2.00]			
Santana 2022	4.1	1.59	19	2.667	0.92	41	13.3%	1.43 [0.66, 2.20]			
Walter 2023	4.48	1.36	97	3.83	1.59	114	49.4%	0.65 [0.25, 1.05]			
Subtotal (95% CI)			146			185	74.5%	0.99 [0.48, 1.50]		-	
Heterogeneity: Tau ² =	0.10; Chi	² = 3.79,	df = 2	(P = 0.1	5); l² = 4	47%					
Test for overall effect:	Z = 3.82	(P = 0.00	01)								
Total (95% CI)			247			397	100.0%	0.83 [0.55, 1.11]		•	
Heterogeneity: Tau ² =	0.00; Chi	² = 5.88,	df = 6	(P = 0.4	4); l ² = (0%					
Test for overall effect:	Z = 5.78	(P < 0.00	001)						-4 -2	0 2 NB TEA	4
Toot for subgroup diffe	ronoo: ($2hi^2 = 0.6$	2 df -	1 (D = 0)	1 4 2 1 12	- 00/				ND IEA	

Test for subgroup differences: $Chi^2 = 0.63$, df = 1 (P = 0.43), l² = 0%



С

		NB			TEA			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
2.3.1 PVB									
Beltran 2017	1.6	1.2	7	2.5	2.4	8	2.2%	-0.90 [-2.79, 0.99]	
Hall 2014	2.667	2.408	10	3.167	2.408	10	1.7%	-0.50 [-2.61, 1.61]	
Loftus 2016	3.5071	4.1961	28	2.93	4.462	80	2.3%	0.58 [-1.26, 2.41]	
Muhly 2019	3	1.52	56	2.33	2.252	114	23.4%	0.67 [0.10, 1.24]	
Subtotal (95% CI)			101			212	29.5%	0.40 [-0.23, 1.03]	•
Heterogeneity: Tau ² =	0.06; Chi	² = 3.32,	df = 3 (P = 0.3	5); l² = ′	10%			
Test for overall effect:	Z = 1.25	(P = 0.21)						
2.3.2 ESPB									
Bliss 2022	4.32	2.53	30	3.38	1.67	30	6.5%	0.94 [-0.14, 2.02]	
Santana 2022	4.067	1.442	19	3.33	0.92	41	15.4%	0.74 [0.03, 1.44]	
Walter 2023	4.48	1.36	97	3.83	1.59	114	48.5%	0.65 [0.25, 1.05]	
Subtotal (95% CI)			146			185	70.5%	0.70 [0.37, 1.03]	\bullet
Heterogeneity: Tau ² =	0.00; Chi	² = 0.26,	df = 2 (P = 0.8	8); l² = (0%			
Test for overall effect:	Z = 4.13	(P < 0.00	01)						
Total (95% CI)			247			397	100.0%	0.63 [0.35, 0.91]	•
Heterogeneity: Tau ² =	0.00; Chi	² = 4.06,	df = 6 (P = 0.6	7); l² = (0%			
Test for overall effect:	Z = 4.47	(P < 0.00	001)						-4 -2 0 2 4 NB TEA
Test for subgroup diffe	erences: C	Chi² = 0.6	8, df =	1 (P = 0).41), l²	= 0%			IND TEA

Fig. 4 Forest plot of pain score on POD 1 (A), POD 2 (B) and POD 3 (C)

in study of Walter et al. [24] and the request for oral medication due to rebound pain after epidural discontinuation [23]. Santana et al. reported that patients in the TEA group consume more opioids72 hours after the operation. The opioid usage after POD 7 was more frequent in the TEA group [24]. The total opioid usage may be higher in the TEA group duration hospitalization [23, 24]. The postoperative opioid usage was another important factor for LOS [41, 42]. However, due to variations in the duration of analgesia catheter use and insufficient data, we

Study or Subgroup		NB		т	EA		N	lean Difference	Меа	n Difference
		SD T	otal	Mean		otal V		V, Random, 95% CI		andom, 95% Cl
3.1.1 PVB			_			_				
Beltran 2017	3.4	1.6	7 10	1.4	1.4	8	4.1%	2.00 [0.47, 3.53]		_
Hall 2014 Muhly 2019	0.14 0.31 0	0.12).175018		0.157 .006673 (0.181 0.015018		23.8% 24.7%	-0.02 [-0.15, 0.12] 0.30 [0.26, 0.35]		• •
Subtotal (95% CI)	0.01 0	.175010	73	.000075			52.6%	0.23 [-0.11, 0.56]		
Heterogeneity: Tau ² Test for overall effect			: 2 (P <	0.00001); l²	2 = 92%					
3.1.2 ESPB										
Bliss 2022	1	0.575	30	0.2125	0.0875		22.7%	0.79 [0.58, 1.00]		
Walter 2023	0.1 0.0	0978309	97	0.28 0.			24.8%	-0.18 [-0.20, -0.16]		
Subtotal (95% CI) Heterogeneity: Tau² : Test for overall effect		= 82.06, df =	127 : 1 (P <	0.00001); l²		144	47.4%	0.30 [-0.65, 1.25]		
Total (95% CI)		·	200			276 1	00.0%	0.29 [-0.05, 0.63]		
Heterogeneity: Tau ²	= 0.12; Chi ² =	: 419.00, df	= 4 (P <	< 0.00001);	l² = 99%				-1 -0.5	
Test for overall effect Test for subgroup dif		,	= 1 (P =	= 0.89), l² =	0%				0.0	0 0.5 1 [NB] Favours [TEA]
5		NB			TEA			Mean Difference	Me	ean Difference
Stuay or Subgroup	Mean) Total	Mear) Tota	l Weight			Random, 95% Cl
3.2.1 PVB										
Beltran 2017	3.4							1.40 [-0.63, 3.43]		
Hall 2014	0.14							-0.02 [-0.13, 0.08]		T .
Muhly 2019 Subtotal (95% CI)	0.333273	0.190182	2 56 73	0.016673	3 0.037545	5 114 132		0.32 [0.27, 0.37] 0.18 [-0.15, 0.51]		
Heterogeneity: Tau² = Test for overall effect:			2 (P < 0.	.00001); l² =	94%					
3.2.2 ESPB										
Bliss 2022	0.678571	0.3875						0.42 [0.27, 0.56]		
Walter 2023 Subtotal (95% CI)	0.0166667	0.0376273	97 127	0.0133333	3 0.0300342	2 114 144		0.00 [-0.01, 0.01] 0.20 [-0.20, 0.61]		
Heterogeneity: Tau ² = Test for overall effect:			1 (P < 0.	.00001); l² =	97%					
Total (95% CI)			200			276	100.0%	0.19 [-0.02, 0.39]		
Heterogeneity: Tau ² =	= 0.04: Chi² =	175.55. df =		0.00001); l²	= 98%				-++	
Test for overall effect:	: Z = 1.75 (P =	= 0.08)							-1 -0.5 Favours	0 0.5 1 [NB] Favours [TEA]
Test for subgroup diffe					TEA	Total	Weight	Mean Difference IV. Random. 95% CI		an Difference Random, 95% Cl
	Mean	NB SD	Total	wean	SD					
Test for subgroup diff C <u>pr Subgroup</u> VB	Mean		Total	Mean	50	TOLAI	Weight			
C ^{or Subgroup} VB	Mean 3.2	SD	Total 7	<u>Mean</u> 3.1	2.3	<u>10tai</u> 8	0.0%	0.10 [-1.84, 2.04]	•	
C <u>pr Subgroup</u> VB Beltran 2017		SD					-		•	
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019	3.2	<u>SD</u> 1.5	7 10 56	3.1	2.3	8 10 114	0.0% 0.4% 2.8%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07]	4	
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% CI) Heterogeneity: Tau ²	3.2 0.14 0.083327 = 0.00; Chi ² =	SD 1.5 0.1 0.1674 : 0.48, df = 2	7 10 56 73	3.1 0.163 0.06	2.3 0.172 0.112636	8 10	0.0% 0.4%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10]	4	
C <u>pr Subgroup</u> VB Beltran 2017 Hali 2014 Muhly 2019 Subtotal (95% CI) Heterogeneity: Tau ² Test for overall effect	3.2 0.14 0.083327 = 0.00; Chi ² =	SD 1.5 0.1 0.1674 : 0.48, df = 2	7 10 56 73	3.1 0.163 0.06	2.3 0.172 0.112636	8 10 114	0.0% 0.4% 2.8%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07]	<	•
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% CI) Heterogeneity: Tau ² Test for overall effect 3.3.2 ESPB	3.2 0.14 0.083327 = 0.00; Chi ² = t: Z = 0.75 (P	SD 1.5 0.1 0.1674 = 0.48, df = 2 = 0.46)	7 10 56 73 2 (P = 0.	3.1 0.163 0.06 .79); I ² = 0%	2.3 0.172 0.112636	8 10 114 132	0.0% 0.4% 2.8% 3.2%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.06]	· · · · · · · · · · · · · · · · · · ·	•
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% Cl) Heterogeneity: Tau ² Test for overall effect 3.3.2 ESPB Bliss 2022	3.2 0.14 0.083327 = 0.00; Chi ² = t: Z = 0.75 (P 0.7125	SD 1.5 0.1 0.1674 = 0.48, df = 2 = 0.46) 0.496429	7 10 56 73 2 (P = 0. 30	3.1 0.163 0.06 .79); I ² = 0% 0.833929	2.3 0.172 0.112636 0.366071	8 10 114 132 30	0.0% 0.4% 2.8% 3.2%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.06]		
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 3.3.2 ESPB Bliss 2022 Walter 2023	3.2 0.14 0.083327 = 0.00; Chi ² = t: Z = 0.75 (P	SD 1.5 0.1 0.1674 = 0.48, df = 2 = 0.46) 0.496429	7 10 56 73 2 (P = 0.	3.1 0.163 0.06 .79); I ² = 0% 0.833929	2.3 0.172 0.112636	8 10 114 132	0.0% 0.4% 2.8% 3.2%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.06]		• • •
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 3.3.2 ESPB Bliss 2022 Walter 2023 Subtotal (95% Cl) Heterogeneity: Tau ² =	3.2 0.14 0.083327 = 0.00; Chi ² = t: Z = 0.75 (P 0.7125 0 = 0.00; Chi ² =	<u>SD</u> 1.5 0.1 0.1674 = 0.48, df = 2 = 0.46) 0.496429 0.0001 = 0.81, df = 7	7 10 56 73 2 (P = 0 30 97 127	3.1 0.163 0.06 .79); I ² = 0% 0.833929 0.02	2.3 0.172 0.112636 0.366071 0.0450513	8 10 114 132 30 114	0.0% 0.4% 2.8% 3.2% 0.1% 96.6%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.06] -0.12 [-0.34, 0.10] -0.02 [-0.03, -0.01]		• • •
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% Cl) Heterogeneity: Tau ² Test for overall effect 3.3.2 ESPB Bliss 2022 Walter 2023 Subtotal (95% Cl) Heterogeneity: Tau ² Test for overall effect	3.2 0.14 0.083327 = 0.00; Chi ² = t: Z = 0.75 (P 0.7125 0 = 0.00; Chi ² =	<u>SD</u> 1.5 0.1 0.1674 = 0.48, df = 2 = 0.46) 0.496429 0.0001 = 0.81, df = 7	7 10 56 73 2 (P = 0. 30 97 127 1 (P = 0.	3.1 0.163 0.06 .79); I ² = 0% 0.833929 0.02	2.3 0.172 0.112636 0.366071 0.0450513	8 10 114 132 30 114 144	0.0% 0.4% 2.8% 3.2% 0.1% 96.6% 96.8%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.06] -0.12 [-0.34, 0.10] -0.02 [-0.03, -0.01] -0.02 [-0.03, -0.01]		
C <u>pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 3.3.2 ESPB Bliss 2022 Walter 2023 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect Total (95% CI)	3.2 0.14 0.083327 = 0.00; Chi ² = t: Z = 0.75 (P 0.7125 0 = 0.00; Chi ² = t: Z = 4.78 (P	SD 1.5 0.1 0.1674 0.48, df = 2 = 0.48, df = 2 = 0.46) 0.496429 0.0001 0.81, df = - < 0.00001)	7 10 56 73 2 (P = 0. 30 97 127 1 (P = 0. 200	3.1 0.163 0.06 (79); I ² = 0% 0.833929 0.02 (37); I ² = 0%	2.3 0.172 0.112636 0.366071 0.0450513	8 10 114 132 30 114 144	0.0% 0.4% 2.8% 3.2% 0.1% 96.6%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.06] -0.12 [-0.34, 0.10] -0.02 [-0.03, -0.01]		
C <u>Pr Subgroup</u> VB Beltran 2017 Hall 2014 Muhly 2019 Subtotal (95% Cl) Heterogeneity: Tau ² Test for overall effect 3.3.2 ESPB Bliss 2022 Walter 2023 Subtotal (95% Cl) Heterogeneity: Tau ² Test for overall effect	3.2 0.14 0.083327 = 0.00; Chi ² = t: Z = 0.75 (P 0.7125 0 = 0.00; Chi ² = t: Z = 4.78 (P = 0.00; Chi ² =	SD 1.5 0.1 0.1674 : 0.48, df = 2 = 0.46) 0.496429 0.0001 : 0.81, df = - < 0.00001) : 3.83, df = 4	7 10 56 73 2 (P = 0. 30 97 127 1 (P = 0. 200	3.1 0.163 0.06 (79); I ² = 0% 0.833929 0.02 (37); I ² = 0%	2.3 0.172 0.112636 0.366071 0.0450513	8 10 114 132 30 114 144	0.0% 0.4% 2.8% 3.2% 0.1% 96.6% 96.8%	0.10 [-1.84, 2.04] -0.02 [-0.15, 0.10] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.06] -0.12 [-0.34, 0.10] -0.02 [-0.03, -0.01] -0.02 [-0.03, -0.01]		0 0.5 [NB] Favours [TEA]

Fig. 5 Forest plot of opioid usage on POD 1 (A), POD 2 (B) and POD 3 (C)

were unable to evaluate the pain and opioid usage after discontinuing both types of analgesia catheters.

Our analysis found a higher risk of PONV needing treatment in the TEA group (Fig. 6) which may relate to the neuraxial administration of opioids [18]. A similar

result was reported by Scarci et al. [29] They found that PONV was observed in 35% of patients who received neuraxial opioids without prophylactic antiemetics [43]. PONV can cause a great deal of discomfort for patients and may hinder their ability to consume food orally. In



Fig. 6 Forest plot of PONV

such cases, intravenous fluids may be required for a longer duration due to poor oral intake [44]. Therefore, PONV has been found to be highly correlated with the LOS [45].

Although TEA provides better pain control compared to continuous ESPB and PVB, catheter placement is considered a technical skill [22] and has a relatively high failure rate [29]. Unintentional dural puncture, a risk factor for spinal cord damage, has been reported at a rate of 0.4-3.4% [8]. ESPB [23] and PVB [16, 17] are less likely to cause damage to the spinal cord as they are placed at a greater distance from the neuraxial axis. The current literature has not reported any permanent neurological defects resulting from ESPB [23] or PVB [16]. Other complications related to ESPB [26] and PVB [27], such as pneumothorax, pleural puncture, epidural or intrathecal spread, hematoma, and vascular puncture, have been reported, but at a lower rate compared to TEA. The common complications associated with PVB catheter placement are vascular puncture (3.8%), pleural puncture (1.1%), and pneumothorax (0.5%) [46]. A pooled review of ESPB identified a case of pneumothorax [47]. However, there is a steep learning curve associated with ESP catheter placement [25] and it takes longer (21 min) to place them bilaterally [24, 28]. Overall, continuous nerve blocks appear to be safer than TEA. Complications such as vascular puncture and pneumothorax are easier to manage than neurological damage. Therefore, ESPB and PVB may be considered safer alternatives.

TEA is currently the most common method of pain control for patients undergoing major thoracic and abdominal surgery [11, 48, 49]. However, with the advancement of ultrasound equipment and concerns about neurological injury, more anesthesiologists are using nerve blocks for these patients [50]. Although several studies have demonstrated the efficacy of nerve blocks [4, 39, 40], the pain characteristics of patients undergoing PE repair are different from those of patients undergoing other major thoracic surgeries. These patients seldom felt severe incision pain but often experience stretch and pressure on the sternum and chest wall [18, 51]. Therefore, it may not be appropriate to directly apply findings from other studies to patients undergoing PE repair. Fortunately, our report demonstrated that continuous nerve blocks are non-inferior to TEA in this patient population. However, there were no RCT conducted. Future studies should be well-designed RCTs that compare TEA and continuous nerve blocks in terms of LOS, pain score, and adverse events in patients undergoing PE repair. Moreover, as these patients often experience longer pain durations, studies should also assess pain scores, opioid consumption, and PONV after the weaning of analgesia catheters.

Limitations

The main limitation of this study is the low number of included studies. In addition, none of the studies were RCTs, and there was a moderate to serious risk of bias in the included trials. Furthermore, the use of data conversion methods may have introduced some limitations to our analysis.

Conclusion

Continuous PVB and ESPB use is associated with reduced hospital stay and PONV, and thus, may be considered alternative to thoracic epidural analgesia in patients with PE repair. However, because of the low quality of studies, well-designed RCT are required to verify the evidence.

Abbreviations

CI	Confidence interval
HI	Haller index
ESPB	Erector spinae plane block
LOS	Length of hospital stay
PVB	Paravertebral block
PCA	Patient-controlled analgesia
PE	Pectus excavatum
POD	Post-operative day
PONV	Post-operative nausea and vomiting
RCT	Randomized controlled trial
ROBINS-I	Risk-of-bias tool for non-randomized studies of interventions
MD	Mean difference
TEA	Thoracic epidural analgesia

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12871-023-02221-x.

Supplementary Material 1

Acknowledgements

Not applicable.

Authors' contributions

CLJ participated in conceptualization, literature review and manuscript writing. SHC and YLH helped in consulting the relevant literature and revised manuscript. YPC helped in conceptualization, literature review, acquisition of funding and manuscript writing. All authors have agreed both to be personally accountable for the author's own contributions.

Funding

This study was supported by a grant from the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TCRD-TPE-112-46).

Data Availability

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

This article does not contain any studies with human subjects.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 22 May 2023 / Accepted: 26 July 2023

Published online: 09 August 2023

References

- 1. Brochhausen C, et al. Pectus excavatum: history, hypotheses and treatment options. Interact Cardiovasc Thorac Surg. 2012;14(6):801–6.
- Kelly RE Jr, Obermeyer RJ, Nuss D. Diminished pulmonary function in pectus excavatum: from denying the problem to finding the mechanism. Ann Cardiothorac Surg. 2016;5(5):466–75.
- Ramadan S et al. Cardiopulmonary function in adolescent patients with pectus excavatum or carinatum. BMJ Open Respir Res, 2021. 8(1).
- 4. Rugyte DC, et al. Systemic postoperative pain management following minimally invasive pectus excavatum repair in children and adolescents: a retrospective comparison of intravenous patient-controlled analgesia and continuous infusion with morphine. Pediatr Surg Int. 2010;26(7):665–9.
- Mao YZ, Tang S, Li S. Comparison of the Nuss versus Ravitch procedure for pectus excavatum repair: an updated meta-analysis. J Pediatr Surg. 2017;52(10):1545–52.
- Stroud AM, et al. Epidural analgesia versus intravenous patient-controlled analgesia following minimally invasive pectus excavatum repair: a systematic review and meta-analysis. J Pediatr Surg. 2014;49(5):798–806.
- Manion SC, Brennan TJ. Thoracic epidural analgesia and acute pain management. Anesthesiology. 2011;115(1):181–8.
- Giebler RM, Scherer RU, Peters J. Incidence of neurologic complications related to thoracic epidural catheterization. Anesthesiology. 1997;86(1):55–63.
- Ruppen W, et al. Incidence of epidural haematoma and neurological injury in cardiovascular patients with epidural analgesia/anaesthesia: systematic review and meta-analysis. BMC Anesthesiol. 2006;6:10.
- Manassero A, et al. Postoperative thoracic epidural analgesia: adverse events from a Single-Center Series of 3126 patients. Local Reg Anesth. 2020;13:111–9.
- 11. Frawley G, Frawley J, Crameri J. A review of anesthetic techniques and outcomes following minimally invasive repair of pectus excavatum (Nuss procedure). Paediatr Anaesth. 2016;26(11):1082–90.

- 12. Yoshizaki M, et al. Bilateral erector spinae plane block using a programmed
- intermittent bolus technique for pain management after Nuss procedure. J Clin Anesth. 2019;57:51–2.
 Lowery DR, et al. Continuous Erector Spinae Plane Blocks for adult Pectus
- Excavatum Repair. Ann Thorac Surg. 2019;108(1):e19–e20.
- Batra RK, Krishnan K, Agarwal A. Paravertebral block. J Anaesthesiol Clin Pharmacol. 2011;27(1):5–11.
- 15. Karmakar MK. Thoracic paravertebral block. Anesthesiology. 2001;95(3):771–80.
- Hall Burton DM, Boretsky KR. A comparison of paravertebral nerve block catheters and thoracic epidural catheters for postoperative analgesia following the Nuss procedure for pectus excavatum repair. Paediatr Anaesth. 2014;24(5):516–20.
- Beltran R, et al. Postoperative pain management in patients undergoing thoracoscopic repair of pectus excavatum: a retrospective analysis of opioid consumption and adverse effects in adolescents. Saudi J Anaesth. 2017;11(4):427–31.
- Muhly WT, et al. Perioperative Management and In-Hospital outcomes after minimally invasive repair of Pectus Excavatum: a Multicenter Registry Report from the Society for Pediatric Anesthesia Improvement Network. Anesth Analq. 2019;128(2):315–27.
- Liang XL, et al. The Analgesic Effects of thoracic paravertebral block versus thoracic epidural anesthesia after thoracoscopic surgery: a Meta-analysis. J Pain Res. 2021;14:815–25.
- 20. Chin KJ, El-Boghdadly K. Mechanisms of action of the erector spinae plane (ESP) block: a narrative review. Can J Anaesth. 2021;68(3):387–408.
- Jain K, Jaiswal V, Puri A. Erector spinae plane block: relatively new block on horizon with a wide spectrum of application - a case series. Indian J Anaesth. 2018;62(10):809–13.
- 22. De Cassai A, et al. Injectate spread in ESP block: a review of anatomical investigations. J Clin Anesth. 2020;61:109669.
- Santana L, Driggers J, Carvalho NF. Pain management for the Nuss procedure: comparison between erector spinae plane block, thoracic epidural, and control. World J Pediatr Surg. 2022;5(4):e000418.
- Walter CM, et al. Retrospective study comparing outcomes of multimodal epidural and erector spinae catheter pain protocols after pectus surgery. J Pediatr Surg. 2023;58(3):397–404.
- Bliss DP Jr, et al. Ultrasound-guided erector spinae plane block versus thoracic epidural analgesia: postoperative pain management after Nuss repair for pectus excavatum. J Pediatr Surg. 2022;57(2):207–12.
- Schwartzmann A, et al. A magnetic resonance imaging study of local anesthetic spread in patients receiving an erector spinae plane block. Can J Anaesth. 2020;67(8):942–8.
- 27. Sorenstua M, et al. Spread of local anesthetics after erector spinae plane block: an MRI study in healthy volunteers. Reg Anesth Pain Med. 2023;48(2):74–9.
- Macaire P, et al. Ultrasound-guided continuous thoracic erector Spinae Plane Block within an enhanced recovery program is Associated with decreased opioid consumption and Improved Patient Postoperative Rehabilitation after Open Cardiac Surgery-A Patient-Matched, controlled before-and-after study. J Cardiothorac Vasc Anesth. 2019;33(6):1659–67.
- Scarci M, Joshi A, Attia R. Patients undergoing thoracic surgery is paravertebral block as effective as epidural analgesia for pain management? Interact Cardiovasc Thorac Surg. 2010;10(1):92–6.
- Page MJ, et al. [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaracion PRISMA 2020: una guia actualizada para la publicacion de revisiones sistematicas]. Rev Panam Salud Publica. 2022;46:e112.
- Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
- Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:14898.
- Sterne JA, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
- Loftus PD, et al. Paravertebral regional blocks decrease length of stay following surgery for pectus excavatum in children. J Pediatr Surg. 2016;51(1):149–53.
- Ladak SS, et al. Incidence of urinary retention in patients with thoracic patient-controlled epidural analgesia (TPCEA) undergoing thoracotomy. Pain Manag Nurs. 2009;10(2):94–8.

- De Leon LE, et al. Risk of urinary recatheterization for thoracic Surgical patients with epidural anesthesia. J Surg Res (Houst). 2020;3(3):163–71.
- Wuethrich PY, Kessler TM, Burkhard FC. The effects of thoracic epidurally administered drugs on urethral sphincter function in women: a pooled analysis. Pain Med. 2013;14(8):1248–53.
- Gold PA, et al. The effect of bladder catheterization on ambulation and venous thromboembolism following total knee arthroplasty: an institutional analysis. J Arthroplasty. 2020;35(65):S197–S200.
- Baidya DK, Khanna P, Maitra S. Analgesic efficacy and safety of thoracic paravertebral and epidural analgesia for thoracic surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2014;18(5):626–35.
- Weber T, et al. Superior postoperative pain relief with thoracic epidural analgesia versus intravenous patient-controlled analgesia after minimally invasive pectus excavatum repair. J Thorac Cardiovasc Surg. 2007;134(4):865–70.
- 41. Densmore JC, et al. Initial surgical and pain management outcomes after Nuss procedure. J Pediatr Surg. 2010;45(9):1767–71.
- Graves CE, et al. Intraoperative intercostal nerve cryoablation during the Nuss procedure reduces length of stay and opioid requirement: a randomized clinical trial. J Pediatr Surg. 2019;54(11):2250–6.
- Grant CRK, Checketts MR. Analgesia for primary hip and knee arthroplasty: the role of regional anaesthesia. Continuing Educ Anaesth Crit Care Pain. 2008;8(2):56–61.
- 44. Gan TJ, et al. Fourth Consensus Guidelines for the management of postoperative nausea and vomiting. Volume 131. Anesthesia & Analgesia; 2020. 2.

- Habib AS et al. Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial (1528 – 1175 (Electronic)).
- Lonnqvist PA, et al. Paravertebral blockade. Failure rate and complications. Anaesthesia. 1995;50(9):813–5.
- 47. Tsui BCH, et al. The erector spinae plane (ESP) block: a pooled review of 242 cases. J Clin Anesth. 2019;53:29–34.
- Kelly RE, et al. Twenty-one years of experience with minimally invasive repair of pectus excavatum by the Nuss procedure in 1215 patients. Ann Surg. 2010;252(6):1072–81.
- Muhly WT, Maxwell LG, Cravero JP. Pain management following the Nuss procedure: a survey of practice and review. Acta Anaesthesiol Scand. 2014;58(9):1134–9.
- Liu D-X, Zhu Z-Q. Ultrasound-guided peripheral trunk block technique: a new approach gradually stepping onto the stage of clinical anesthesia. Ibrain. 2021;7(3):211–26.
- Nakanii M, Namba T, Uemura S. Pain caused by the Pectus Bar Implant after the Nuss Procedure for Pectus Excavatum among Junior High and High School Children. Kawasaki J Med Welf. 2011;17(1):15–21.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.